Abcam PLC represents a strong set of values and corporate philosophy. As a global leader in the supply of life science research tools, Abcam is committed to enabling scientific discoveries and improving human health. Their values include innovation, collaboration, integrity, and customer focus. Abcam fosters a culture of excellence, empowering their employees to make a positive impact. With their customer-centric approach, Abcam strives to provide high-quality products and exceptional service to researchers worldwide. By upholding these values and embodying their corporate philosophy, Abcam PLC continues to make significant contributions to the scientific community and drive advancements in the field of life sciences.

Abcam PLC is primarily present in multiple countries and regions around the world. Its global presence includes the United Kingdom, the United States, China, Japan, Germany, France, and Australia, among others. Abcam PLC has established a strong presence in these regions through its extensive network of distributors, sales offices, and research collaborations. With a global footprint, Abcam PLC efficiently serves its customers, scientists, and researchers worldwide, providing them with innovative and high-quality research tools and reagents to support their scientific endeavors.

Abcam PLC, a leading provider of life science research tools, has achieved several significant milestones. Over the years, the company has expanded its product portfolio, establishing a comprehensive range of high-quality antibodies, proteins, assays, and reagents. Abcam PLC has also formed numerous collaborations with renowned academic and clinical institutions, enabling innovative research discoveries. The company's commitment to quality and innovation has led to the development of key technologies, including RabMAb® antibodies, which offer superior specificity and sensitivity. Moreover, Abcam PLC has successfully expanded its global presence, with offices and distribution centers across major research hubs worldwide. These milestones validate Abcam PLC's position as a trusted partner in advancing scientific knowledge.

Abcam PLC is a renowned life sciences company based in the United Kingdom. Established in 1998, Abcam has emerged as a global leader in the supply of research tools to the scientific community. With a focus on providing high-quality antibodies, proteins, and other essential reagents, Abcam has developed a vast product portfolio catering to various research areas, including cancer, neuroscience, and immunology. The company's commitment to innovation and quality has enabled it to forge strong partnerships with academic institutions and biopharmaceutical companies worldwide. Abcam's dedication to advancing scientific knowledge and supporting researchers has solidified its position as a prominent player in the life sciences industry.

The main competitors of Abcam PLC in the market include Thermo Fisher Scientific, Merck KGaA, and Bio-Rad Laboratories.

Abcam PLC is primarily active in the life sciences industry. As a leading provider of research tools, the company specializes in the production and distribution of high-quality antibodies, proteins, and other biological reagents. Abcam PLC serves a diverse range of sectors within the life sciences field, including academia, pharmaceuticals, biotechnology, and clinical diagnostics. With its broad portfolio of products and global presence, Abcam PLC supports scientists and researchers worldwide in their quest for breakthrough discoveries and advancements in various areas such as cancer research, neuroscience, stem cells, immunology, and more.

The business model of Abcam PLC is focused on the production and distribution of high-quality antibodies and other life science research tools. Abcam works closely with academic and industrial researchers worldwide to provide essential reagents needed for conducting experiments and advancing scientific discoveries in the fields of genomics, proteomics, and immunology. By offering a broad range of products, including primary and secondary antibodies, proteins, peptides, and assays, Abcam aims to support researchers in their quest for better understanding and treatment of diseases. Through its online platform and global distribution network, Abcam ensures that its products reach scientists efficiently, enabling them to accelerate their research and make meaningful contributions to their respective fields.

KGV Abcam iznosi 0.

Koeficijent cijene i prometa Abcam iznosi 6,49.

AlleAktien Qualitätsscore za Abcam je 4/10.

Promet očekivana Abcam iznosi 427,28 mil. GBP.

Dobit trenutno ne može biti izračunata za Abcam.

Abcam PLC is a company specializing in the development and marketing of antibodies and other research reagents. The company was founded in 1998 and is headquartered in Cambridge, UK. It has branches in several countries, including the US, China, and Japan. Abcam offers its customers a wide range of products and services focused on immunology, cell biology, epigenetics, and neurobiology. The company is divided into two business areas: research products and diagnostics. Under the research products category, Abcam offers a wide range of antibodies, proteins, kits, and reagents used by scientists and researchers worldwide. The company offers over 130,000 antibodies focusing on a variety of research areas. Additionally, the company provides a variety of resources and tools on its website, such as data sheets, protocols, and videos, to help researchers make their work more effective. Abcam's diagnostics division includes a wide range of products and services aimed at improving disease diagnosis and finding therapeutic solutions. The company's advanced technologies include innovative proteomics and epitope mapping tools, as well as cutting-edge platforms for developing immunassays. Abcam strives to offer its customers the best products and services. For this reason, the company has implemented strict quality controls and tests to ensure that all products meet the highest standards. The company also offers a 100% satisfaction guarantee and provides free replacement products or refunds if customers are not satisfied with their purchases. Abcam is also actively involved in nonprofit research. The company has established the Abcam Research Awards, which allow scientists to receive financial support for their groundbreaking research. Abcam's business model is focused on meeting customer needs while promoting the company's growth. The company aims to maintain its position as a leading provider of antibodies and other research reagents and expand into new areas such as diagnostics and therapeutics. It relies on a solid infrastructure, qualified employees, and strategic partnerships to successfully serve its customers. In summary, Abcam is a leading provider of research products and diagnostics focusing on immunology, cell biology, epigenetics, and neurobiology. The company offers its customers a wide range of products and services centered around strict quality controls and tests, as well as a 100% satisfaction guarantee. Abcam's business model is focused on innovation, offering high-quality products and services, and meeting customer needs.

Abcam isplaćuje dividendu od 0 GBP raspoređenu preko isplata godišnje.

Dividenda za Abcam trenutno se ne može izračunati ili tvrtka ne isplaćuje dividendu.

ISIN od Abcam je GB00B6774699.

WKN od Abcam je A1C605.

Oznaka burze tvrtke Abcam je ABC.L.

U posljednjih 12 mjeseci Abcam je isplatio dividendu u iznosu od 0,04 GBP . To odgovara prinosu dividende od oko 0,29 %. Za sljedećih 12 mjeseci Abcam će vjerojatno isplatiti dividendu u iznosu od 0,49 GBP.

Trenutni prinos dividende od Abcam iznosi 0,29 %.

Abcam isplaćuje dividende kvartalno. One se isplaćuju u mjesecima prosinac, travanj, prosinac, travanj.

Abcam je isplatio dividendu svake godine u posljednjih 4 godina.

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0,49 GBP. To odgovara dividendnom prinosu od 4,00 %.

Abcam se pripisuje sektoru 'Zdravlje'.

Da bi primili posljednju dividendu od Abcam od 17. 04. 2020. u iznosu od 0,036 GBP, trebali ste imati dionicu u portfelju prije Ex-dana 19. 03. 2020..

Posljednja isplata dividende izvršena je 17. 04. 2020..

U godini 2023 su od Abcam 0 GBP isplaćene kao dividende.

Dividende od Abcam isplaćuju se u GBP.